EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

[Translated article] Exploring New Horizons in Allergic Contact Dermatitis Treatment: The Role of Emerging Therapies

I Rivera-Ruiz, A Gil-Villalba, F J Navarro-Triviño

Actas Dermo-Sifiliográficas · 2025

DOI: 10.1016/j.ad.2025.05.016 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Actas Dermo-Sifiliográficas, 2025. Verfasst von I Rivera-Ruiz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, Hospital Universitario Reina Sofía de Córdoba, Córdoba, Spain; Inflammatory Immune-mediated Chronic Skin Diseases Laboratory,…. Hauptthemen laut MEDLINE: Dermatitis, Allergic Contact. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The resistant and recalcitrant nature of severe allergic contact dermatitis (ACD) makes treatment challenging. With advances in the understanding of the cellular and molecular pathogenesis of this dermatosis, new therapeutic options are emerging. In particular, the use of biologic drugs such as dupilumab and small molecule inhibitors, such as JAK inhibitors have gained momentum given the cross-cutting inhibition of multiple cytokine actions. This article aims to review the current available data on the use of biologic drugs and small molecule inhibitor drugs in the management of ACD. Results suggest that iJAKs, such as abrocitinib, tofacitinib, upadacitinib, and baricitinib; although biologic drugs, such as dupilumab show significant promise in refractory ACD, more long-term clinical trials are needed to confirm their safety and efficacy profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, Allergic ContactHumansAntibodies, Monoclonal, HumanizedPyrimidinesJanus Kinase InhibitorsPiperidinesAzetidinesPurinesSulfonamidesPyrazolesBoron CompoundsCyclopropanesBiological ProductsHeterocyclic Compounds, 3-Ring

Stichwörter der Autor:innen

Allergic contact dermatitisBiologic drugsDermatitis de contacto alérgicaFármacos biológicosInhibidores de JAKJAK inhibitorsNew therapiesNuevas terapias

Substanzen

dupilumabAntibodies, Monoclonal, HumanizedPyrimidinesJanus Kinase InhibitorsPiperidinesAzetidinesPurinestofacitinibbaricitinibSulfonamides

Autor:innen und Institutionen

  • Dermatology Department, Hospital Universitario Reina Sofía de Córdoba, Córdoba, Spain; Inflammatory Immune-mediated Chronic Skin Diseases Laboratory, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)/R…
  • Dermatology Department, Hospital Universitario San Cecilio, Granada, Spain.
  • Contact Eczema and Immunoallergic Diseases Department, Dermatology, Hospital Universitario San Cecilio, Granada, Spain; Instituto de Investigación Biosanitaria ibs, Granada, Spain. Electronic address: fntmed@gmail.com.

Zitieren

APA

Rivera-Ruiz, I., Gil-Villalba, A., & Navarro-Triviño, F. J. (2025). [Translated article] Exploring New Horizons in Allergic Contact Dermatitis Treatment: The Role of Emerging Therapies. Actas Dermo-Sifiliográficas. https://doi.org/10.1016/j.ad.2025.05.016

Vancouver

Rivera-Ruiz I, Gil-Villalba A, Navarro-Triviño FJ. [Translated article] Exploring New Horizons in Allergic Contact Dermatitis Treatment: The Role of Emerging Therapies. Actas Dermo-Sifiliográficas. 2025. doi:10.1016/j.ad.2025.05.016

BibTeX
@article{RiveraRuiz2025,
  author = {Rivera-Ruiz, I and Gil-Villalba, A and Navarro-Triviño, F J},
  title = {[Translated article] Exploring New Horizons in Allergic Contact Dermatitis Treatment: The Role of Emerging Therapies},
  journal = {Actas Dermo-Sifiliográficas},
  year = {2025},
  doi = {10.1016/j.ad.2025.05.016}
}
Kostenlos starten →